Production (Stage)
ARS Pharmaceuticals, Inc.
SPRY
$14.98
$0.463.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 971,120.00% | 297,063.33% | 8,460.00% | 128.31% | -98.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 971,120.00% | 297,063.33% | 8,460.00% | 128.31% | -98.51% |
| Cost of Revenue | 2.23% | 1.95% | -1.71% | -12.65% | 3.28% |
| Gross Profit | 513.28% | 442.84% | 14.22% | 14.13% | -7.18% |
| SG&A Expenses | 143.09% | 51.16% | -16.13% | -1.64% | 51.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 100.28% | 36.54% | -12.04% | -5.48% | 32.65% |
| Operating Income | 56.34% | 95.43% | 15.59% | 5.96% | -34.56% |
| Income Before Tax | 69.09% | 115.24% | 20.32% | 15.94% | -17.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 68.51% | 114.71% | 20.32% | 15.94% | -17.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.51% | 114.71% | 20.32% | 15.94% | -17.23% |
| EBIT | 56.34% | 95.43% | 15.59% | 5.96% | -34.56% |
| EBITDA | 56.86% | 95.55% | 15.59% | 5.97% | -34.56% |
| EPS Basic | 69.26% | 113.92% | 28.41% | 39.29% | 34.58% |
| Normalized Basic EPS | 65.49% | 107.84% | 20.79% | 32.56% | 27.94% |
| EPS Diluted | 51.52% | 97.80% | 28.41% | 39.29% | 34.58% |
| Normalized Diluted EPS | 49.10% | 92.32% | 20.79% | 32.56% | 27.94% |
| Average Basic Shares Outstanding | 1.62% | 1.81% | 9.54% | 33.70% | 71.28% |
| Average Diluted Shares Outstanding | 7.32% | 7.54% | 9.54% | 33.70% | 71.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |